Orchard Therapeutics plc (ORTX)

Market Cap	71.71M
Revenue (ttm)	16.15M
Net Income (ttm)	-179.13M
Shares Out	126.69M
EPS (ttm)	-1.41
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	463,711
Open	0.580
Previous Close	0.600
Day's Range	0.540 - 0.600
52-Week Range	0.360 - 1.230
Beta	0.69
Analysts	Buy
Price Target	3.40 (+500.71%)
Earnings Date	n/a

About ORTX

Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified cellular drug product to treat the patient's disease through a single administration. It provides Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company's clinica...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Prof. Bobby Gaspar Ph.D., M.D.
• Employees: 259
• Stock Exchange: NASDAQ
• Ticker Symbol: ORTX

Financial Performance

In 2021, ORTX's revenue was $1.68 million, a decrease of -35.45% compared to the previous year's $2.60 million. Losses were -$144.58 million, -4.87% less than in 2020.

Analyst Forecast

According to 13 analysts, the average rating for ORTX stock is "Buy." The 12-month stock price forecast is $3.4, which is an increase of 500.71% from the latest price.

Price Target

$3.4

(500.71% upside)

Analyst Consensus: Buy